Chaoju Eye Care Holdings Ltd (2219) Fair Value & Analysis
Healthcare · HK · Market cap HK$1.7B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 3 days ago
Fair value updated Aug 13, 2026, revised from HK$5.78 to HK$5.79 (+0.2%) since Aug 5, 2026. Share price +1.8% over the past month.
A solid business, screening 123% undervalued on our models.
What matters now
- The price is below even our cautious bear case (HK$3.72). The market is more pessimistic than our downside scenario.
- Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (HK$3.72 to HK$8.48) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$2.08 – HK$12.18 · fair‑value band HK$3.72 – HK$8.48 · the HK$2.60 price screens below the HK$5.79 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Chaoju Eye Care Holdings Ltd (2219) currently trades at HK$2.60, while our model-based Fair Value estimate is HK$5.79, implying the stock looks roughly 123.1% undervalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Chaoju Eye Care Holdings Ltd generated revenue of HK$1.4B at a net margin of 13.5%. Revenue declined 1.4% year over year. It earns a return on equity of 7.5%. The balance sheet holds a net cash position of HK$279M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$3.72 (bear case) to HK$8.48 (bull case); at HK$2.60, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 10% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 123%, 2219 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (HK$5.29) versus Dividend Discount (HK$1.38). Highest evidence: Growth DCF (80).
Notify me when 2219 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 52
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Chaoju Eye Care Holdings Limited, together with its subsidiaries, owns and operates a network of ophthalmic hospitals and centers in the People's Republic of China.
Full company description
Chaoju Eye Care Holdings Limited, together with its subsidiaries, owns and operates a network of ophthalmic hospitals and centers in the People's Republic of China. The company offers in-patient and out-patient ophthalmic medical services; and consumer ophthalmic services, including treatments and prevention for various ophthalmic disorders, such as refractive and presbyopia correction, and myopia prevention and control. It also provides basic ophthalmic services for the treatment of a range of eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases, dry eye syndrome, and oculoplastic and pediatric eye diseases. In addition, the company engages in investment management activities; and the sale of equipment, optical products, and medical consumables. Chaoju Eye Care Holdings Limited was founded in 1988 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Chaoju Eye Care Holdings Ltd reported revenue of HK$1.4B in FY2025 versus HK$998M in FY2021, a compound +8.1%/yr. Reported net income was HK$183M in FY2025, compounding +3.2%/yr from FY2021.
Watch 2219: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 266 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Tenet Healthcare Corporation THC | $266.79 | $330.25 | +24% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.97 | R$47.31 | +39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,565 | ₹2,955 | -65% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.70 THB | 18.57 THB | -6% |
Compare Chaoju Eye Care Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Chaoju Eye Care Holdings Ltd (2219) overvalued or undervalued?
What is the fair value of 2219?
What is the quality score of 2219?
What is the revenue of Chaoju Eye Care Holdings Ltd (2219)?
What is the net profit margin of 2219?
Does Chaoju Eye Care Holdings Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Chaoju Eye Care Holdings Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.